Artelo Biosciences, Inc.
ARTLHealthcareNASDAQBiotechnology · Last scanned Oct 26, 2026
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Artelo Biosciences, Inc. focuses on Biotechnology services and products. Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, develops and commercializes therapeutics that target lipid-signaling pathways in the United States. At a $1.4M market cap, Artelo Biosciences, Inc. ranks as a micro-cap company within healthcare. The company's product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of cancer-related anorexia; and ART12.11, a cocrystal composition of cannabidiol and tetramethylpyrazine for the treatment anxiety, depression, post-traumatic stress disorder PTSD, epilepsy and insomnia, and other potential indications.
Market Cap
$1.4M
Beta
-0.07
P/E (TTM)
—
P/E (Fwd)
-2.90
EPS (TTM)
$-136.26
EPS (Fwd)
$-0.88
ROE
-705.7%
ROA
-127.9%
Cash
$4.2M
Total Debt
$49,000
Free CF
-$8.6M
52W Change
-97.2%
Annual Financials
Cash vs Debt
Where ARTL stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, ARTL finished 85.58% below its 150-day moving average ($18.45) and 88.64% below its 200-day moving average ($23.41). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is ARTL overbought or oversold?
At the October 20, 2026 close, ARTL's RSI(14) was 0.0, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Artelo Biosciences, Inc. holds $4.2M in cash against $49K in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Free cash flow is running at -$8.6M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -705.7% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
With a beta below 0.7, Artelo Biosciences, Inc. typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Artelo Biosciences, Inc.'s trajectory.